Research progress on risk factors of intravesical recurrence and intravesical instillation after radical nephroureterectomy for upper tract urothelial carcinoma

doi:10.3760/cma.j.issn.1007-1245.2023.14.005

Abstract

Abstract:

The intravesical recurrence (IVR) rate of upper tract urothelial carcinoma is relatively high after radical nephroureterectomy. Currently, there are many studies on the risk factors of IVR, but many of them are controversial. The risk stratification and prediction model are not yet mature, and a personalized intravesical instillation scheme guided by it has not been formed. Intravesical perfusion can reduce the recurrence in bladder, but there are controversies about the times, timing, and drugs. The prediction, bladder perfusion, surgery, and follow-up of IVR after radical nephroureterectomy are mainly draw lessons from primary bladder cancer. An independent standardized scheme has not yet been formed. The risk factors of IVR and intravesical instillation scheme have become the foci in recent years. This article reviews them.

Key words:

Urothelial carcinoma, Intravesical instillation, Radical nephroureterectomy, Intravesical recurrence, Risk factors, Progress

摘要：

上尿路尿路上皮癌行根治性肾输尿管切除术后膀胱内复发（intravesical recurrence，IVR）率较高。目前，IVR的危险因素研究较多，但许多因素存在争议，危险分层及预测模型还不成熟，未形成以此为指导的个性化的膀胱灌注方案。膀胱灌注可减少IVR，但灌注次数、时机、药物等方面存在争议。根治术后IVR的预测、膀胱灌注、手术及随访等主要借鉴原发膀胱癌，尚未形成一套独立的标准化方案。IVR的危险因素及膀胱灌注方案成为近年的研究热点，本文对其进行综述。

关键词:

尿路上皮癌, 膀胱灌注, 根治性肾输尿管切除术, 膀胱内复发, 危险因素, 进展

Xu Meng, Xing Shaoqiang, Zhu Xingwang, Zhang Xuefeng, Wang Shipeng.

Research progress on risk factors of intravesical recurrence and intravesical instillation after radical nephroureterectomy for upper tract urothelial carcinoma [J]. International Medicine and Health Guidance News, 2023, 29(14): 1944-1949.

徐萌邢绍强祝兴旺张学峰王世鹏.

上尿路尿路上皮癌根治术后膀胱内复发的危险因素及膀胱灌注的研究进展 [J]. 国际医药卫生导报, 2023, 29(14): 1944-1949.

References

[1] Azizi M, Cheriyan SK, Peyton CC, et al. Optimal management of upper tract urothelial carcinoma: an unmet need[J]. Curr Treat Options Oncol, 2019, 20(5):40. DOI: 10.1007/s11864-019-0637-2.
[2] 任乾, 曾蜀雄, 汤仕杰, 等. 上尿路尿路上皮癌术后膀胱复发危险因素分析[J].第二军医大学学报,2018,39(5): 469-473. DOI:10.16781/j.0258-879x.2018.05.0469.
[3] Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma [J]. Eur Urol, 2015, 67(6): 1122-1133. DOI: 10.1016/j.eururo.2014. 11.035.
[4] 王安莲,王勋,刘赟,等. 上尿路尿路上皮癌术后膀胱内复发的危险因素及预防性膀胱灌注化疗的意义[J]. 国际泌尿系统杂志,2019,39(3):457-460. DOI:10.3760/cma.j.issn.1673-4416.2019.03.021.
[5] Wang Q, Zhang T, Wu J, et al. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China[J]. BMC Urol, 2019,19(1):24. DOI: 10.1186/s12894-019-0457-5.
[6] Sato G, Yoshida T, Yanishi M, et al. Preoperative pyuria predicts for intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy without a history of bladder cancer[J]. Clin Genitourin Cancer, 2020, 18(2): e167-e173. DOI: 10.1016/j.clgc.2019.09.017.
[7] Lee CH, Ku JY, Jeong CW, et al. Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis [J]. Clin Genitourin Cancer, 2017,15(6): e1055-e1061. DOI: 10.1016/j.clgc.2017.07.009.
[8] Zhao H, Jiao B, Liu K, et al. Intravesical recurrence factors and outcome after radical nephroureterectomy for upper tract urothelial carcinoma: multivariate analysis with propensity score matching[J]. Front Oncol, 2022,12: 984014. DOI: 10.3389/fonc.2022.984014.
[9] Fan B, Huang Y, Wen S, et al. Predictive value of preoperative positive urine cytology for development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma: a prognostic nomogram based on a retrospective multicenter cohort study and systematic meta-analysis [J]. Front Oncol, 2021, 11: 731318. DOI: 10.3389/fonc.2021.731318.
[10] Jiang Y, Yao Z, Zhu X, et al. Risk factors and oncological outcome for intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: a propensity score-matched case control study[J]. Int J Surg, 2020,76: 28-34. DOI: 10.1016/j.ijsu.2020.02.015.
[11] 郑铎, 尚攀峰, 刘隽垚, 等. 上尿路尿路上皮癌患者根治性肾输尿管切除术后膀胱内复发危险因素的Meta分析[J].中国循证医学杂志,2018,18(3):305-313. DOI: 10.7507/1672-2531.201710121.
[12] 王健, 邵长富, 周典晟, 等. 上尿路尿路上皮癌根治术后膀胱内复发的危险因素分析[J].中华泌尿外科杂志,2021,42(8):571-575. DOI:10.3760/cma.j.cn112330-20200419- 00308.
[13] Song Y, Han J, Qin C, et al. Whether diagnostic ureteroscopic biopsy and ureteroscopy without biopsy have different impacts on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy? [J]. World J Urol, 2022, 40(8): 2135-2137. DOI: 10.1007/s00345-022-04064-6.
[14] Nowak Ł, Krajewski W, Chorbińska J, et al. The impact of diagnostic ureteroscopy prior to radical nephroureterectomy on oncological outcomes in patients with upper tract urothelial carcinoma: a comprehensive systematic review and meta-analysis[J]. J Clin Med, 2021,10(18): 4197. DOI: 10.3390/jcm10184197.
[15] Katims AB, Say R, Derweesh I, et al. Risk factors for intravesical recurrence after minimally invasive nephroureterectomy for upper tract urothelial cancer (ROBUUST collaboration) [J]. J Urol, 2021, 206(3): 568-576. DOI: 10.1097/JU.0000000000001786.
[16] Lai SC, Wu PJ, Liu JY, et al. Oncological impact of different distal ureter managements during radical nephroureterectomy for primary upper urinary tract urothelial carcinoma[J]. World J Clin Cases, 2020, 8(21): 5104-5115. DOI: 10.12998/wjcc.v8.i21.5104.
[17] Yanagi M, Hamasaki T, Akatsuka J, et al. Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma[J]. BMC Urol, 2021, 21(1): 167. DOI: 10.1186/s12894-021-00932-2.
[18] Long X, Qi L, Zu X, et al. Prevention of recurrent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinoma: an individualized selection strategy based on patient risk stratification is needed [J]. Urol Int, 2017, 98(3): 312-319. DOI: 10.1159/000451004.
[19] 赖世聪. 关于上尿路尿路上皮癌术后膀胱癌对患者预后的影响和预测其发生的危险因素及模型的研究[D]. 北京: 中国医学科学院,2021.
[20] Zhang X, Bu R, Liu Z, et al. Development and validation of a model for predicting intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: a retrospective study in one center with long-term follow-up [J]. Pathol Oncol Res, 2020, 26(3): 1741-1748. DOI: 10.1007/s12253-019-00748-4.
[21] Ishioka J, Saito K, Kijima T, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy [J]. BJU Int, 2015, 115(5): 705-712. DOI: 10.1111/bju.12707.
[22] 吴鹏杰. 原发性上尿路尿路上皮癌发生膀胱癌的危险因素及术后膀胱灌注化疗周期的研究[D]. 北京:北京协和医学院,2015. DOI:10.7666/d.Y2818357.
[23] 李冰清, 董俊友, 黄奋人. 上尿路移行上皮癌[J].青岛医学院学报,1983,(02):64-67. DOI: 10.13361/j.qdyxy.1983. 02.016.
[24] Sakamoto N, Naito S, Kumazawa J, et al. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study [J]. Int J Urol, 2001, 8(5): 212-216. DOI: 10.1046/j.1442-2042.2001.00286.x.
[25] O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)[J]. Eur Urol, 2011, 60(4):703-710. DOI: 10.1016/j.eururo.2011.05.064.
[26] Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase Ⅱ trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial[J]. J Clin Oncol, 2013,31(11):1422-1427. DOI: 10.1200/JCO.2012.45.2128.
[27] Miyamoto K, Ito A, Wakabayashi M, et al. A Phase Ⅲ trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase Ⅲ) [J]. Jpn J Clin Oncol, 2018, 48(1): 94-97. DOI: 10.1093/jjco/hyx158.
[28] 吴肖冰, 葛力源, 戴黎阳, 等. 上尿路尿路上皮癌术后预防性膀胱灌注化疗的临床意义[J].中华泌尿外科杂志, 2017, 38(4): 286-289. DOI: 10.3760/cma.j.issn.1000-6702. 2017.04.012.
[29] Wu P, Zhu G, Wei D, et al. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis [J]. J BUON, 2015,20(5):1229-1238.
[30] Yoo SH, Jeong CW, Kwak C, et al. Intravesical chemotherapy after radical nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and network meta-analysis [J]. J Clin Med, 2019, 8(7):1059. DOI: 10.3390/jcm8071059.
[31] 黎桂源, 蒋双键, 莫承强, 等. 原发性上尿路上皮癌术后膀胱灌注化疗在预防膀胱癌复发中的作用——系统综述及Meta分析[J].现代泌尿外科杂志,2019,24(9):733-740. DOI: 10.3969/j.issn.1009-8291.2019.09.012.
[32] 黄雪强, 李常颖, 王一, 等. 膀胱灌注化疗对输尿管尿路上皮癌根治术后复发膀胱癌的影响[J].临床泌尿外科杂志, 2014, 29(12): 1088-1090. DOI: 10.13201/j.issn.1001-1420.2014.12.015.
[33] Wu J, Xu PH, Luo WJ, et al. Intravesical recurrence after radical nephroureterectomy of upper urinary tract urothelial carcinoma: a large population-based investigation of clinicopathologic characteristics and survival outcomes[J]. Front Surg, 2021, 8: 590448. DOI: 10.3389/fsurg.2021.590448.
[34] 王仙友,王国栋,刘丁乙,等. 基于倾向性评分匹配法的上尿路尿路上皮癌根治术后膀胱复发对预后的影响分析[J]. 浙江医学,2021,43(5):507-510,515. DOI:10.12056/j.issn.1006-2785.2021.43.5.2020-3532.
[35] 刘振华,杨玉帛,鄢世兵,等. 上尿路尿路上皮癌围手术期预测预后因素的评估与应用:华西经验分享[J]. 现代泌尿外科杂志, 2018, 23(10): 732-734, 751. DOI:10.3969/j.issn.1009-8291.2018.10.003.
[36] Deng X, Yang X, Cheng Y, et al. Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract[J]. Int J Clin Exp Med, 2014,7(12): 4734-4746.
[37] Moriarty MA, Uhlman MA, Bing MT, et al. Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy [J]. BMC Urol, 2015,15:45. DOI: 10.1186/s12894-015-0039-0.
[38] Nadler N, Oedorf K, Jensen JB, et al. Intraoperative mitomycin c bladder instillation during radical nephroureterectomy is feasible and safe[J]. Eur Urol Open Sci, 2021, 34: 41-46. DOI: 10.1016/j.euros.2021.09.013.
[39] Yamamoto S, Sakamoto S, Imamura Y, et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma[J]. Int J Urol, 2019, 26(8):791-796. DOI: 10.1111/iju.14014.
[40] Freifeld Y, Ghandour R, Singla N, et al. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy [J]. Urol Oncol, 2020, 38(9): 737.e11-737.e16. DOI: 10.1016/j.urolonc.2020.05.002.
[41] Noennig B, Bozorgmehri S, Terry R, et al. Evaluation of intraoperative versus postoperative adjuvant mitomycin c with nephroureterectomy for urothelial carcinoma of the upper urinary tract [J]. Bladder Cancer, 2018, 4(4): 389-394. DOI: 10.3233/BLC-180174.
[42] Packiam VT, Leibovich BC, Thompson RH, et al. GEMINI: an open-label, single-arm, phase Ⅱ trial of intraoperative gemcitabine intravesical instillation in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma [J]. J Clin Oncol, 2020, 38(6): TPS594. DOI: 10.1200/JCO.2020.38.6_suppl.TPS594.
[43] Fan B, Teng Q, Sun M, et al. Assessment of therapeutic benefit and option strategy on intravesical instillation for preventing bladder cancer recurrence after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma [J]. J Oncol, 2022:1755368. DOI: 10.1155/2022/1755368.
[44] van Doeveren T, van Leeuwen PJ, Aben K, et al. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial [J]. Contemp Clin Trials Commun, 2018, 9: 121-129. DOI: 10.1016/j.conctc.2018.01.007.
[45] 孔垂泽,刘奔,李振华,等. 预防肾盂输尿管癌术后再发膀胱癌的手术方法研究[J]. 中华泌尿外科杂志,2006,27(4):250-252. DOI:10.3760/j:issn:1000-6702.2006.04.009.
[46] Gulamhusein A, Silva P, Cullen D, et al. Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy[J]. BJU Int, 2020,126(6):739-744. DOI: 10.1111/bju.15162.
[47] Del Giudice F, van Uem S, Li S, et al. Contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy in patients with upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy: analysis of us claims on perioperative outcomes and health care costs [J]. Clin Genitourin Cancer, 2022, 20(2): 198.e1-198.e9. DOI: 10.1016/j.clgc.2021.11.016.
[48] Kenigsberg AP, Carpinito G, Gold SA, et al. Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: low but increasing utilization during minimally invasive nephroureterectomy [J]. Urol Oncol, 2022,40(10): 452.e17-452.e23. DOI: 10.1016/j.urolonc.2022.06.006.
[49] 廖国栋, 俞蔚文, 张琦, 等. 单次与多次膀胱灌注方案对原发性上尿路尿路上皮癌术后预后的影响[J].中国临床药理学与治疗学,2017,22(4):461-465.
[50] Huang Y, Cen J, Liu Z, et al. A comparison of different prophylactic intravesical chemotherapy regimens for bladder cancer recurrence after nephroureterectomy for primary upper tract urothelial carcinomas: a retrospective 2-center study [J]. Technol Cancer Res Treat, 2019,18: 1533033819844483. DOI: 10.1177/1533033819844483.
[51] 任冬. 多次与单次膀胱灌注化疗对上尿路尿路上皮癌术后膀胱内复发的影响:一项Meta分析[D]. 重庆:重庆医科大学,2021.
[52] Harraz AM, El-Shabrawy M, El-Nahas AR, et al. Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a randomized clinical trial [J]. Clin Genitourin Cancer, 2019,17(6): e1108-e1115. DOI: 10.1016/j.clgc.2019.07.019.
[53] 姜仁慧,孙德康,王建明,等. 卡介苗膀胱灌注防治上尿路移行细胞癌术后复发[J]. 肿瘤防治杂志, 2001, 8(4): 407-408. DOI: 10.3969/j.issn.1673-5269.2001.04.027.
[54] Bree KK, Hensley PJ, Brooks NA, et al. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer [J]. BJU Int, 2021,128(5):568-574. DOI: 10.1111/bju.15344.
[55] Miyake M, Tatsumi Y, Matsumoto H, et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma [J]. BJU Int, 2018, 121(5): 764-773. DOI: 10.1111/bju.14111.
[56] Sfakianos JP, Cha EK, Iyer G, et al. Genomic characterization of upper tract urothelial carcinoma [J]. Eur Urol, 2015, 68(6):970-977. DOI: 10.1016/j.eururo.2015.07.039.
[57] Shigeta K, Matsumoto K, Ogihara K, et al. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma [J]. Cancer Sci, 2021,112(3):1084-1094. DOI: 10.1111/cas.14782.
[58] Shigeta K, Matsumoto K, Tanaka N, et al. Profiling the biological characteristics and transitions through upper tract tumor origin, bladder recurrence, and muscle-invasive bladder progression in upper tract urothelial carcinoma [J]. Int J Mol Sci, 2022, 23(9):5154. DOI: 10.3390/ijms23095154.
[59] 刘会范, 徐培元, 赵高贤. 冬凌草热疗与膀胱灌注化疗预防上尿路移行细胞癌术后复发的比较[J].中国老年学杂志,2009,29(4):452-453. DOI: 10.3969/j.issn.1005-9202. 2009.04.029.
[60] 方冬, 李学松. 上尿路尿路上皮癌诊断与治疗中国专家共识[J].中华泌尿外科杂志,2018,39(07):485-488. DOI: 10.3760/cma.j.issn.1000-6702.2018.07.002.
[61] 周利群,王行环,李磊,等.上尿路尿路上皮癌诊断治疗指南//黄健,张旭.中国泌尿外科和男科疾病诊断治疗指南: 2022版[M].北京:科学出版社,2022:272-291.